These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 2415199)

  • 1. Platelet sensitivity to a prostacyclin analogue in systemic sclerosis.
    Belch JJ; O'Dowd A; Forbes CD; Sturrock RD
    Br J Rheumatol; 1985 Nov; 24(4):346-50. PubMed ID: 2415199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of inhibitory actions of prostacyclin and a new prostacyclin analogue on the aggregation of human platelet in whole blood.
    Saniabadi AR; Belch JJ; Lowe GD; Barbenel JC; Forbes CD
    Haemostasis; 1987; 17(3):147-53. PubMed ID: 2440771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The PGI2-analogue iloprost and the TXA2-receptor antagonist sulotroban synergistically inhibit TXA2-dependent platelet activation.
    Stürzebecher S; Witt W
    Prostaglandins; 1988 Dec; 36(6):751-60. PubMed ID: 2469101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of equimolar concentrations of iloprost, prostacyclin, and prostaglandin E1 on human platelet function.
    Fisher CA; Kappa JR; Sinha AK; Cottrell ED; Reiser HJ; Addonizio VP
    J Lab Clin Med; 1987 Feb; 109(2):184-90. PubMed ID: 2433373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential inhibition of the platelet activation sequence: shape change, micro- and macro-aggregation, by a stable prostacyclin analogue (Iloprost).
    Pedvis LG; Wong T; Frojmovic MM
    Thromb Haemost; 1988 Apr; 59(2):323-8. PubMed ID: 2455359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional and ligand binding studies suggest heterogeneity of platelet prostacyclin receptors.
    Armstrong RA; Lawrence RA; Jones RL; Wilson NH; Collier A
    Br J Pharmacol; 1989 Jul; 97(3):657-68. PubMed ID: 2474350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of platelet aggregation by a new stable prostacyclin introduced in therapy of patients with progressive scleroderma.
    Keller J; Kaltenecker A; Schricker KT; Neidhardt B; Hornstein OP
    Arch Dermatol Res; 1985; 277(4):323-5. PubMed ID: 2408588
    [No Abstract]   [Full Text] [Related]  

  • 8. The effect of PGI2 and PGI2 analogues with increased stability on platelet cAMP content and aggregation.
    Blaskó G; Nemesánszky E; Szabó G; Stadler I; Pálos LA
    Thromb Res; 1980 Mar; 17(5):673-81. PubMed ID: 6247777
    [No Abstract]   [Full Text] [Related]  

  • 9. The pharmacological effects of cicaprost, an oral prostacyclin analogue, in patients with Raynaud's syndrome secondary to systemic sclerosis--a preliminary study.
    Lau CS; McLaren M; Saniabadi A; Scott N; Belch JJ
    Clin Exp Rheumatol; 1991; 9(3):271-3. PubMed ID: 1879086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of anti-aggregatory effects of PGI2, PGI3 and iloprost on human and rabbit platelets.
    Kobzar G; Mardla V; Järving I; Samel N
    Cell Physiol Biochem; 2001; 11(5):279-84. PubMed ID: 11684817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The novel effect of a new prostacyclin analogue ZK36374 on the aggregation of human platelets in whole blood.
    Saniabadi AR; Lowe GD; Belch JJ; Forbes CD; Prentice CR; Barbenel JC
    Thromb Haemost; 1983 Oct; 50(3):718-21. PubMed ID: 6196854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of taprostene, a stable prostacyclin analogue, on haemodynamics, platelet function and arachidonate metabolism in healthy volunteers.
    Virgolini I; Fitscha P; Sinzinger H; Barth H
    Eur J Clin Pharmacol; 1990; 38(4):347-50. PubMed ID: 2111774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of the inhibitory effects of prostacyclin and carbacyclin on platelet adhesion to collagen.
    Karniguian A; Simmons P; Legrand YJ; Moncada S; Caen JP
    Prostaglandins; 1982 Dec; 24(6):827-36. PubMed ID: 6300971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostacyclin-synthesis stimulating plasma factor and platelet sensitivity in preeclampsia.
    Dadak C; Kefalides A; Sinzinger H
    Biol Res Pregnancy Perinatol; 1985; 6(2):65-9. PubMed ID: 3893552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased prostacyclin metabolites and decreased red cell deformability in patients with systemic sclerosis and Raynauds syndrome.
    Belch JJ; McLaren M; Anderson J; Lowe GD; Sturrock RD; Capell HA; Forbes CD
    Prostaglandins Leukot Med; 1985 Jan; 17(1):1-9. PubMed ID: 3883365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of prostacyclin on platelet-activating factor induced rabbit and platelet aggregation.
    Bussolino F; Camussi G
    Prostaglandins; 1980 Nov; 20(5):781-91. PubMed ID: 6258196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum from patients with Raynaud's phenomenon inhibits prostacyclin production.
    Rustin MH; Bull HA; Machin SJ; Koro O; Dowd PM
    J Invest Dermatol; 1987 Dec; 89(6):555-9. PubMed ID: 3316410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of oral aspirin dose on platelet aggregation and vascular prostacyclin (PGI2) synthesis in humans and rabbits.
    Ellis EF; Wright KF; Jones PS; Richardson DW; Ellis CK
    J Cardiovasc Pharmacol; 1980; 2(4):387-97. PubMed ID: 6156337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro studies of thromboresistance: the role of prostacyclin (PGI2) in platelet adhesion to cultured normal and virally transformed human vascular endothelial cells.
    Curwen KD; Gimbrone MA; Handin RI
    Lab Invest; 1980 Mar; 42(3):366-74. PubMed ID: 6244462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relative activity of prostacyclin (PGI2) and a stable analogue 6beta-PGI1 on the gastrointestinal and cardiovascular systems.
    Whittle BJ; Boughton-Smith NK; Moncada S; Vane JR
    J Pharm Pharmacol; 1978 Sep; 30(9):597-9. PubMed ID: 29109
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.